Teriflunomide is the active metabolite of leflunomide, and it functions as a immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated to treat multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide. It is grouped under the following drug class(es): Immunosuppressants. Its therapeutic use is listed as multiple sclerosis agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Flucyamide, Aubagio and teriflunomidum. Its PubChem CID is 54684141.
Teriflunomide
| CAS No | 163451-81-8 |
|---|---|
| Molecular Formula | C12H9F3N2O2 |
| Molecular Weight | 270.21 g/mol |
| Synonyms | (Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Teriflunomide is the active metabolite of leflunomide, and it functions as a immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated to treat multiple sclerosis, specifically relapsing forms.
The listed CAS number is 163451-81-8.
The listed molecular formula is C12H9F3N2O2.
The listed molecular weight is 270.21 g/mol.
(Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide.
The source lists Flucyamide, Aubagio and teriflunomidum.